Evidence map›Paper›PMID 27932444›Full record

ArticleEMBO molecular medicine2017

Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages.

Maria Antsiferova, Aleksandra Piwko-Czuchra, Michael Cangkrama, Mateusz Wietecha, Dilara Sahin, Katharina Birkner, Valerie C Amann, Mitchell Levesque, Daniel Hohl, Reinhard Dummer and 1 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Bridging the divide: unveiling mutual immunological pathways of cancer and pregnancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  8. Review
  9. Activin A-Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in genetics · 2021
    Article
  14. The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021
    Review
  15. Review
  16. Article
  17. Monocytes and Macrophages in Cancer: Unsuspected Roles.Advances in experimental medicine and biology · 2020
    Review
  18. Article
  19. The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Maria AntsiferovaDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Aleksandra Piwko-CzuchraDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Michael CangkramaDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Mateusz WietechaDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Dilara SahinDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Katharina BirknerDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Valerie C AmannDepartment of Dermatology, University Hospital, Zurich, Switzerland.
Mitchell LevesqueDepartment of Dermatology, University Hospital, Zurich, Switzerland.
Daniel HohlDepartment of Dermatology, University of Lausanne, Lausanne, Switzerland.
Reinhard DummerDepartment of Dermatology, University Hospital, Zurich, Switzerland.
Sabine WernerDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland sabine.werner@biol.ethz.ch.ORCID 0000-0001-7397-8710
ETH Zurich · CHUniversity Hospital of Zurich · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activin has emerged as an important player in different types of cancer, but the underlying mechanisms are largely unknown. We show here that activin overexpression is an early event in murine and human skin tumorigenesis. This is functionally important, since activin promoted skin tumorigenesis in mice induced by the human papillomavirus 8 oncogenes. This was accompanied by depletion of epidermal γδ T cells and accumulation of regulatory T cells. Most importantly, activin increased the number of skin macrophages via attraction of blood monocytes, which was prevented by depletion of CCR2-positive monocytes. Gene expression profiling of macrophages from pre-tumorigenic skin and bioinformatics analysis demonstrated that activin induces a gene expression pattern in skin macrophages that resembles the phenotype of tumor-associated macrophages in different malignancies, thereby promoting angiogenesis, cell migration and proteolysis. The functional relevance of this finding was demonstrated by antibody-mediated depletion of macrophages, which strongly suppressed activin-induced skin tumor formation. These results demonstrate that activin induces skin carcinogenesis via attraction and reprogramming of macrophages and identify novel activin targets involved in tumor formation.

Indexed as

CarcinogenesisAnimalsBiopsyComputational BiologyGene Expression ProfilingHumansInhibin-beta SubunitsMacrophagesMiceSkin NeoplasmsT-Lymphocytesinhibin beta A subunitInhibin-beta Subunitsactivinmacrophageskin cancertumor microenvironment

Identifiers

PMID27932444
PMCPMC5210090
OpenAlexW2560186680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.